Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy

Purpose: It has been hypothesized that tumor cells expressing Fas ligand (FasL) might be able to counterattack and neutralize tumor-infiltrating lymphocytes. We assessed the effect of FasL tumor counterattack on the clinical outcome of interleukin-2 (IL-2)–based immunotherapy in metastatic renal cell carcinoma. Experimental Design: Tumor core needle biopsies were obtained before IL-2–based immunotherapy in 86 patients and repeated within the first cycle in 57 patients. Tumor cells expressing FasL and intratumoral lymphocyte subsets expressing CD4, CD8, CD56, and CD57 were analyzed by immunohistochemistry. Results: At baseline, negative FasL staining in tumor cells was seen in 10 of 86 (12%) biopsies, whereas intense FasL staining was seen (a) in fewer than 10% of tumor cells in 26 (30%) biopsies; (b) in 11 to 50% of tumor cells in 25 (29%) biopsies; (c) in 51 to 90% of tumor cells in 18 (21%) biopsies; and (d) in >90% of tumor cells in 7 (8%) biopsies. On treatment, tumor FasL expression did not change from baseline levels. Moreover, tumor FasL expression was not correlated with objective response or survival whereas the absolute number of CD4+, CD8+, CD56+, and CD57+ cells per mm2 tumor tissue at baseline was significantly higher in responding patients compared with nonresponding patients (P = 0.01, P = 0.008, P = 0.015, and P < 0.001, respectively). During the first course of immunotherapy, the absolute number of CD4+, CD8+, and CD57+ cells per mm2 tumor tissue was significantly higher in responding patients compared with nonresponding patients (P = 0.034, P < 0.001, and P < 0.001, respectively). However, no correlation was observed between the number of intratumoral lymphocytes and tumor FasL expression level. Conclusion: These observations do not support the hypothesis that FasL tumor “counterattack” has an effect on the clinical outcome in metastatic renal cell carcinoma during IL-2–based immunotherapy.

[1]  R. Fisker,et al.  Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma , 2004, Cancer Immunology, Immunotherapy.

[2]  M. Mottolese,et al.  Altered Expression of FAS System Is Related to Adverse Clinical Outcome in Stage I-II Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy , 2004, Clinical Cancer Research.

[3]  T. Sejima,et al.  Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma , 2003, International journal of urology : official journal of the Japanese Urological Association.

[4]  Veronica Huber,et al.  Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles , 2002, The Journal of experimental medicine.

[5]  S. Maher,et al.  Activation‐induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack , 2002, Immunology and cell biology.

[6]  R. Henriksson,et al.  Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  T. Whiteside,et al.  Tumor-induced death of immune cells: its mechanisms and consequences. , 2002, Seminars in cancer biology.

[8]  F. Koga,et al.  Fas labeling status does not correlate with apoptosis of renal cell carcinoma in vivo. , 2001, Anticancer research.

[9]  F. Saint,et al.  Immunohistochemical detection of Fas and Fas ligand in sarcomatoid renal cell carcinoma , 2001, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[10]  N. Restifo.  Countering the 'counterattack' hypothesis , 2001, Nature Medicine.

[11]  P. Möller,et al.  CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies , 2001, Cell Death and Differentiation.

[12]  T. Rafnar,et al.  Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells , 2000, British Journal of Cancer.

[13]  D. Khayat,et al.  A comparative study of Fas and Fas‐ligand expression during melanoma progression , 2000, The British journal of dermatology.

[14]  E. Solary,et al.  Cutting Edge: The Tumor Counterattack Hypothesis Revisited: Colon Cancer Cells Do Not Induce T Cell Apoptosis Via the Fas (CD95, APO-1) Pathway1 , 2000, The Journal of Immunology.

[15]  N. Won,et al.  Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors. , 2000, Archives of pathology & laboratory medicine.

[16]  N. Restifo.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape , 2000, Nature Medicine.

[17]  T. Enomoto,et al.  Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms , 2000, British Journal of Cancer.

[18]  M. Monden,et al.  Cell Lines and Tissue Specimens the Status of Fas and Fas Ligand Expression Can Predict Recurrence of Hepatocellular Carcinoma , 2022 .

[19]  P. Krammer,et al.  Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[20]  T. Whiteside,et al.  Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. , 1999, Cancer research.

[21]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Tschopp,et al.  Fas and Fas ligand expression in tumor cells and in vascular smooth‐muscle cells of colonic and renal carcinomas , 1999, International journal of cancer.

[23]  N. Bander,et al.  Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  D. Nicol,et al.  Expression of apoptotic regulatory molecules in renal cell carcinoma: Elevated expression of Fas ligand , 1999, Immunology and cell biology.

[25]  F. Shanahan,et al.  The Fas counterattack: cancer as a site of immune privilege. , 1999, Immunology today.

[26]  S. Rosenberg,et al.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand. , 1999, Cancer research.

[27]  M. Colombo,et al.  Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. , 1998, Journal of immunology.

[28]  C. Brady,et al.  The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. , 1998, Journal of immunology.

[29]  T. Whiteside,et al.  Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. , 1998, The Journal of clinical investigation.

[30]  D. Smith,et al.  Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies. , 1998, Journal of immunology.

[31]  H. Kalthoff,et al.  Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. , 1998, Cancer research.

[32]  C. Stoeckert,et al.  FasL — Too much of a good thing? , 1997, Nature Medicine.

[33]  T. Griffith,et al.  The role of FasL-induced apoptosis in immune privilege. , 1997, Immunology today.

[34]  Erwin G. Van Meir,et al.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? , 1997, The Journal of clinical investigation.

[35]  D. Green,et al.  Human lung carcinomas express Fas ligand. , 1997, Cancer research.

[36]  C. Stoeckert,et al.  FasL--too much of a good thing? Transplanted grafts of pancreatic islet cells engineered to express Fas ligand are destroyed not protected by the immune system. , 1997, Nature medicine.

[37]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[38]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[39]  S. Rosenberg,et al.  Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. , 1989, Cancer research.

[40]  H. J. G. GUNDERSEN,et al.  Some new, simple and efficient stereological methods and their use in pathological research and diagnosis , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.